Baird Upgrades Exactech (EXAC) to Outperform
More News related to EXAC
- Baird Upgrades Exactech (EXAC) to Outperform
- Exactech (EXAC) Tops Q3 EPS by 1c; Issues Mixed Guidance for Q4 and FY
- Exactech (EXAC) reports Q3 EPS of $0.21; Guides
- Exactech Q3 Revenue $42.4M; Net Income $2.7M or $0.21 EPS
- Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
Baird upgrades Exactech (Nasdaq: EXAC) from Neutral to Outperform. Price target increased from $16 to $22.
To see more analyst ratings on EXAC Click Here.
Exactech, Inc. engages in the development, manufacture, marketing, distribution, and sale of orthopedic implant devices, related surgical instrumentation, and biologic services to hospitals and physicians in the United States and internationally.
Related Categories
UpgradesStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
